JPS6213328B2 - - Google Patents
Info
- Publication number
- JPS6213328B2 JPS6213328B2 JP52140786A JP14078677A JPS6213328B2 JP S6213328 B2 JPS6213328 B2 JP S6213328B2 JP 52140786 A JP52140786 A JP 52140786A JP 14078677 A JP14078677 A JP 14078677A JP S6213328 B2 JPS6213328 B2 JP S6213328B2
- Authority
- JP
- Japan
- Prior art keywords
- licorice
- component
- clove
- ferrous sulfate
- gastric ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 22
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 22
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 22
- 229940010454 licorice Drugs 0.000 claims description 22
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 17
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 13
- 244000223014 Syzygium aromaticum Species 0.000 claims description 13
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 13
- 239000011790 ferrous sulphate Substances 0.000 claims description 13
- 201000005917 gastric ulcer Diseases 0.000 claims description 13
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 13
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 13
- 239000002131 composite material Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 241000202807 Glycyrrhiza Species 0.000 description 21
- 239000003814 drug Substances 0.000 description 15
- 239000004615 ingredient Substances 0.000 description 12
- 239000009517 FM 100 Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 6
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 4
- 239000001263 FEMA 3042 Substances 0.000 description 4
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 4
- 229940033123 tannic acid Drugs 0.000 description 4
- 235000015523 tannic acid Nutrition 0.000 description 4
- 229920002258 tannic acid Polymers 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 3
- 229960002028 atropine sulfate Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940069445 licorice extract Drugs 0.000 description 3
- 230000007721 medicinal effect Effects 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- YXMMAVURUUXKKN-UHFFFAOYSA-J copper chlorophyll sodium Chemical compound [Na+].[Na+].[Cu+2].[N-]1C2=C(C=3C(C(C)C(=CC=4C(=C(C=C)C(=C5)N=4)C)N=3)CCC([O-])=O)C(C([O-])=O)C([O-])=C2C(C)=C1C=C1C(CC)=C(C)C5=N1 YXMMAVURUUXKKN-UHFFFAOYSA-J 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000002536 noncholinergic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- BUJCVBRLTBAYCW-UHFFFAOYSA-N 3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxyphenoxy)propan-1-one Chemical compound COC1=CC=CC=C1OC(CO)C(=O)C1=CC=C(O)C(OC)=C1 BUJCVBRLTBAYCW-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 229960000530 carbenoxolone Drugs 0.000 description 1
- 229940127243 cholinergic drug Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001914 gastric parietal cell Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は胃潰瘍治療複合剤に関するものであり
特に夫々成分Ａ，Ｂ，Ｃとして以下記述する硫酸
第一鉄、丁字および甘草を含有する胃潰瘍治療複
合剤を提供するものである。
成分Ａ、即ち硫酸第一鉄は鉄分欠乏に対する処
方として一般的に知られている。
成分Ｂ、即ち丁字は整腸剤あるいは香辛料とし
て使われている。
成分Ｃ、即ち甘草は鎮痛、吐痰あるいは下剤の
効果を有すると考えられ、又、香辛料の成分とし
て多く使用される。
最近、例えばカーボエノキソロン
（carbenoxolone）グリシルレチン酸
（glycyrrheticacid）K2あるいはFM100の如く、
種々の担体に甘草のエキスを含ませたものが胃潰
瘍の処方に使用されている。しかし、本発明に係
る複合剤はこれらのものとは全く異なるものであ
る。すなわちこれら薬剤は甘草のみを成分として
いるが、本発明に係る胃潰瘍治療複合剤は、これ
ら薬剤よりはるかに少量の甘草を成分とするほ
か、上述した如く硫酸第一鉄および丁字をも成分
として含有している。しかも、この胃潰瘍治療複
合剤にあつては、従来、硫酸第一鉄とタンニン酸
とが併用できないとされているにもかかわらず、
タンニン酸13％含有の丁字と硫酸第一鉄とが併用
され、また甘草と金属塩とが併用できないとされ
ているにもかかわらず、甘草と硫酸第一鉄とが併
用されている。さらに従来、丁字は消化性潰瘍患
者にとり禁忌とされているにもかかわらず、丁字
が成分に採り入れられているのである。
本発明の発明者は成分Ａ，Ｂ，Ｃの種々の複合
剤に関する研究を行い、成分Ａ及びＣのみを使用
した場合には治癒効果は無いが、成分Ａ及びＢを
使用した複合剤（以下CDと記述する）には幾分
の治療効果があること、さらに成分Ａ，Ｂ，Ｃを
使用した複合剤（以下CD1と記述する）は胃潰瘍
の処方に著大なる相乗協調効果を示すことを確認
した。前記複合剤CDあるいはCD1のこの治癒作
用のメカニズムは未だ明白ではないが、制酸剤あ
るいは非コリン剤のメカニズムとは全く異なるも
のであると思われる。
後述する複合剤CD1の治癒試験の結果により、
CD1は制酸剤、抗ペプシン成分（カラギーニン）
（carrageenin）、非コリン剤（硫酸アトロピン）
（atropine sulfate）等と比較して著大なる効果を
有することが確認できた。その治癒率は従来最も
効果のあるとされていた薬FM100より良好であ
つた。
本発明に係る胃潰瘍治療複合剤CD1は成分Ａ，
ＢおよびＣを調合したものであり、たとえば粉末
状とした成分Ａ，ＢおよびＣの所要量を各別に衡
量し、これらを機械的に混合して得られるもので
ある。そしてこの複合剤を胃潰瘍治療複合剤とし
て投薬するにはそれを錠剤、オブラートに包みこ
んだ粉状あるいは粒状として投与することが望ま
しく、また、この目的のために使用する医薬製剤
上受容し得る担体はコーンスターチあるいはスタ
ーチペーストである。
動物試験の手順は酢酸潰瘍（いわゆる重症潰
瘍）における試験手順と同様であり、その試験手
順の詳細は日本のケー・タカギによる1969年「製
薬学」19.418を参照して得られる。
本発明に係る試験において、体重200〜230gm
の雄のウイスターラツトにエーテル麻酔を施して
開腹手術を行い、次に30％の酢酸0.05mlを腺胃に
おける漿膜下組織層に注入し、腹部を縫合した後
それらのラツトを普通に飼育した。
0.5％C.M.C.溶液に懸濁させたCD1あるいはCD
は１日に２度経口投与され、又、その対照動物は
担体だけを与えられた。そして15日間後、それら
の動物は潰瘍の治癒率を観察するために開腹され
た。その結果は実例として下記の表に要約してい
る。
〔実例 〕
複合剤CDは成分Ａ：88％、成分Ｂ：12％のも
のが上述の酢酸潰瘍における試験手順で試験さ
れ、下記の表はその結果を示したものである。
The present invention relates to a gastric ulcer therapeutic complex, and particularly provides a gastric ulcer therapeutic complex containing ferrous sulfate, clove, and licorice, described below as components A, B, and C, respectively. Component A, ferrous sulfate, is commonly known as a remedy for iron deficiency. Ingredient B, clove, is used as an intestinal regulator or a spice. Ingredient C, licorice, is thought to have analgesic, phlegm-reducing, or laxative effects, and is often used as a component of spices. Recently, such as carbenoxolone glycyrrhetic acid K2 or FM100,
Licorice extract in various carriers has been used in the treatment of gastric ulcers. However, the composite agent according to the present invention is completely different from these. In other words, these drugs contain only licorice as an ingredient, but the gastric ulcer treatment complex according to the present invention contains a much smaller amount of licorice than these drugs, and also contains ferrous sulfate and clove as ingredients, as mentioned above. are doing. Moreover, in this gastric ulcer treatment complex, although it has been said that ferrous sulfate and tannic acid cannot be used together,
Clove containing 13% tannic acid and ferrous sulfate are used together, and licorice and ferrous sulfate are used together even though it is said that licorice and metal salts cannot be used together. Furthermore, even though clove has traditionally been contraindicated for patients with peptic ulcer disease, clove has been included as an ingredient. The inventor of the present invention conducted research on various composite agents of ingredients A, B, and C, and found that there is no healing effect when only ingredients A and C are used, but a composite agent using ingredients A and B (hereinafter referred to as CD (hereinafter referred to as CD) has some therapeutic effect, and a combination drug containing components A, B, and C (hereinafter referred to as CD1) has a significant synergistic effect in the treatment of gastric ulcers. confirmed. The mechanism of this healing effect of the combination drug CD or CD1 is not yet clear, but it appears to be completely different from that of antacids or non-cholinergic drugs. Based on the results of the healing test of the composite drug CD1, which will be described later,
CD1 is an antacid and anti-pepsin component (carrageenin)
(carrageenin), non-cholinergic agent (atropine sulfate)
It was confirmed that it has a significant effect compared to other drugs such as (atropine sulfate). Its cure rate was better than that of FM100, a drug that was previously considered to be the most effective. The gastric ulcer therapeutic complex CD1 according to the present invention has components A,
It is a mixture of B and C, and is obtained by, for example, weighing the required amounts of powdered components A, B, and C separately and mechanically mixing them. In order to administer this composite agent as a gastric ulcer treatment composite agent, it is desirable to administer it in the form of tablets, powder wrapped in wafers, or granules, and carriers acceptable for pharmaceutical preparations used for this purpose. is corn starch or starch paste. The animal test procedure is similar to the test procedure for acetic acid ulcer (so-called severe ulcer), and details of the test procedure can be obtained with reference to K. Takagi, Japan, 1969 "Pharmaceutical Science" 19.418. In the test according to the present invention, body weight 200-230gm
Male Wistar rats were anesthetized with ether and underwent laparotomy, then 0.05 ml of 30% acetic acid was injected into the subserosal tissue layer of the glandular stomach, the abdomen was sutured, and the rats were housed normally. CD1 or CD suspended in 0.5% CMC solution
was administered orally twice a day, and the control animals received vehicle only. After 15 days, the animals were opened to observe the rate of ulcer healing. The results are illustratively summarized in the table below. [Example] A composite CD containing 88% component A and 12% component B was tested according to the above-mentioned test procedure for acetic acid ulcers, and the table below shows the results.
複合剤CD1は成分Ａ：68％、成分Ｂ：９％、成
分Ｃ：23％のものが実例と同様な手順で試験さ
れ、下記の表はその結果を示したものである。
Composite agent CD1 containing 68% component A, 9% component B, and 23% component C was tested in the same manner as in the example, and the table below shows the results.
【表】
尚、上述した試験に対する比較と参考のために
二、三の慣用されている胃潰瘍治療剤を15日間投
与した場合に治癒率を下記に示す。
１ 珪酸アルミニウム（1000mg／Kg／o.s.）
11.4％
２ 硫酸アトロピン（20mg／Kg／s.c.） 26.7％
３ 銅クロロフイル−ナトリウム（500mg／Kg／
o.s.） 39.8％
４ グリシルレチン酸（Glycyrrheticacid）K2
（700mg／Kg／o.s.） 33.7％
〔備考〕 このデータは既報の日本の「製薬
学」19・418（1969）による。
さらにFM100における期間的変動に関する試
験結果を表に掲げる。[Table] For comparison and reference with respect to the above-mentioned test, the cure rate is shown below when a few commonly used gastric ulcer therapeutics were administered for 15 days. 1 Aluminum silicate (1000mg/Kg/os)
11.4% 2 Atropine sulfate (20mg/Kg/sc) 26.7% 3 Copper chlorophyll-sodium (500mg/Kg/sc)
os) 39.8% 4 Glycyrrhetic acid K2
(700mg/Kg/os) 33.7% [Note] This data is based on the previously published Japanese "Pharmaceutical Science" 19, 418 (1969). Furthermore, the test results regarding periodic fluctuations in FM100 are listed in the table.
【表】
すなわち実例によると、FM100を用いた場
合、治癒率は41.2％、Ｐ値は0.02以下であるのに
対し、実例によれば、CD1を用いた場合の治癒
率は55.7％、Ｐ値は0.001以下である。したがつ
てFM100に較べCD1の薬効ははるかにすぐれて
いるものであることはこれらの実験例から明らか
であり、FM100の治癒率に関する表の実験例
をも考慮に入れれば、この結果は頗る確度の高い
ものである。さらに、このCD1を、慣用されてい
る二、三の胃潰瘍治療剤と比較してみても、たと
えば銅クロロフイル−ナトリウムの治癒率は39.8
％であつて、CD1の治癒率55.7％はこれより明ら
かに優越している。
以上は、CD1の顕著な薬効を、FM100などの
如き従来の胃潰瘍治療剤との比較において述べた
ものであるが、本発明に係るCD1には、更に以下
に述べるごとき諸特徴がある。
(A) 甘草の含有量が甘草を主体とした従来の治療
剤より極めて少量であること。
実例で用いたCD1：100mg／Kgには23％の
甘草を含むから、甘草の使用量は23mg／Kgであ
る。一方、実例で用いたFM100の量は200
mg／Kgであつた。しかるに、甘草のエキスから
成るFM100は、通常約10倍量の甘草粉末より
抽出されるので、CD1の含有する甘草の量は、
FM100の含有量の
（２３／２００×１０≒）１／１００
にすぎない。ところで甘草エキスを主体とした
従来の治療剤では、甘草に含まれる副腎皮質ホ
ルモン（ｄ′ｅsoxycorticost′ｅrone）類似物質
よつて水腫（edema）のごとき副作用を伴なう
ため、投薬上極めて慎重を必要としたことを考
えれば、甘草の含有量の少ないということは、
CD1の極めて優れた属性の１つとなるのであ
る。なお、CD1に含まれる甘草の量は上記のよ
うに少量であるから、既述したCD1の顕著な薬
効は、甘草単体によつて生じたものでないこと
は明らかである。また、表に示したように、
CDのみから生じた薬効でないことも明らかで
ある。すなわちCD1の顕著な薬効は、硫酸第一
鉄（成分Ａ）、丁字（成分Ｂ）および甘草（成
分Ｃ）の交互作用によるものであると言うこと
ができる。
(B) 併用すべきでないとされる成分、あるいは胃
潰瘍治療剤として不適当な成分を含有するこ
と。
(a) 硫酸第一鉄と丁字との併用
硫酸第一鉄とタンニン酸とは併用できない
とされている。しかるに丁字には、約13％の
タンニン酸が含まれているから、硫酸第一鉄
（成分Ａ）と丁字（成分Ｂ）とを併用した点
は、従来の処方上における禁忌を破つた本発
明の従来にない特徴の１つである。
(b) 甘草と金属塩（metallic salt）との併用両
者は併用不可とされている。しかるに本発明
に係るCD1では、甘草（成分Ｃ）と硫酸第一
鉄（成分Ａ）とを併用している。それ故、こ
の点も本発明の特徴に挙げることができる。
(c) 丁字は、胃壁細胞を刺激し、胃酸の分泌を
促す作用がある。しかるに本発明に係るCD1
は、胃潰瘍治療剤でありながら丁字（成分
Ｂ）を含むので、極めて特徴的である。
このように本発明に係る胃潰瘍治療複合剤は、
調剤上の既成の常識に反し、硫酸第一鉄、丁字お
よび甘草を成分としたものであり、上記のように
薬効は極めて顕著であるにもかかわらず、甘草を
主体とした従来の胃潰瘍治療剤に見られるような
副作用は全く伴わない極めてすぐれた治療剤であ
る。
なお、上記CD1の人に対する有効投与量は、体
重１Kg当り100mgであることが既に投与例をもと
に確認され、その治療効果も認められている。[Table] In other words, according to the actual example, when using FM100, the cure rate is 41.2% and the P value is 0.02 or less, whereas according to the actual example, when using CD1, the cure rate is 55.7% and the P value is 0.02 or less. is less than 0.001. Therefore, it is clear from these experimental examples that the medicinal efficacy of CD1 is far superior to that of FM100, and if we also take into account the experimental examples in the table regarding the cure rate of FM100, this result is highly accurate. It has a high value. Furthermore, when comparing this CD1 with a few commonly used gastric ulcer treatment drugs, for example, the cure rate of copper chlorophyll sodium was 39.8.
%, and the cure rate of CD1, 55.7%, is clearly superior to this. The remarkable medicinal effects of CD1 have been described above in comparison with conventional gastric ulcer therapeutics such as FM100, but the CD1 according to the present invention has further characteristics as described below. (A) The content of licorice is much lower than that of conventional therapeutic agents based on licorice. The CD1 used in the example: 100mg/Kg contains 23% licorice, so the amount of licorice used is 23mg/Kg. On the other hand, the amount of FM100 used in the example was 200
It was mg/Kg. However, FM100, which consists of licorice extract, is normally extracted from about 10 times the amount of licorice powder, so the amount of licorice contained in CD1 is
It is only (23/200×10≒) 1/100 of the content of FM100. However, conventional therapeutic agents based on licorice extract are accompanied by side effects such as edema due to substances similar to adrenal corticosteroid (d'esoxycorticost'erone) contained in licorice, so extreme caution is required when administering the drug. Considering this, the low content of licorice means that
This is one of CD1's outstanding attributes. Furthermore, since the amount of licorice contained in CD1 is small as described above, it is clear that the remarkable medicinal effects of CD1 described above are not caused by licorice alone. Also, as shown in the table,
It is also clear that the drug's efficacy does not result from CD alone. In other words, it can be said that the remarkable medicinal efficacy of CD1 is due to the interaction of ferrous sulfate (component A), clove (component B), and licorice (component C). (B) Contains ingredients that should not be used together or ingredients that are inappropriate as a treatment for gastric ulcers. (a) Combination use of ferrous sulfate and clove It is said that ferrous sulfate and tannic acid cannot be used together. However, since clove contains approximately 13% tannic acid, the combination of ferrous sulfate (component A) and clove (component B) is an advantage of the present invention, which breaks the contraindications in conventional prescriptions. This is one of the unprecedented features of (b) Combination of licorice and metal salt It is prohibited to use both together. However, in CD1 according to the present invention, licorice (component C) and ferrous sulfate (component A) are used together. Therefore, this point can also be cited as a feature of the present invention. (c) Cloves have the effect of stimulating gastric parietal cells and promoting the secretion of gastric acid. However, CD1 according to the present invention
Although it is a therapeutic agent for gastric ulcers, it is very distinctive because it contains the character C (ingredient B). As described above, the gastric ulcer therapeutic complex according to the present invention,
Contrary to the conventional wisdom regarding preparations, it contains ferrous sulfate, clove, and licorice as ingredients, and although its medicinal effects are extremely remarkable as mentioned above, conventional gastric ulcer treatment drugs based on licorice It is an extremely excellent therapeutic agent with no side effects such as those seen in Furthermore, it has already been confirmed based on administration examples that the effective dose for people with CD1 is 100 mg/kg body weight, and its therapeutic effect has also been recognized.
Claims (1)
種類を有効成分として含有する胃潰瘍治療複合
剤。 ２ 医薬製剤上受容し得る不活性担体を含有し、
かつ錠剤に形成した特許請求の範囲第１項に記載
の胃潰瘍治療複合剤。[Claims] 1. At least 3 of ferrous sulfate, clove, and licorice.
A gastric ulcer treatment complex containing various types of active ingredients. 2 Contains a pharmaceutically acceptable inert carrier,
The composite agent for treating gastric ulcer according to claim 1, which is formed into a tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14078677A JPS5476815A (en) | 1977-11-25 | 1977-11-25 | Composite agent for treating stomach ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14078677A JPS5476815A (en) | 1977-11-25 | 1977-11-25 | Composite agent for treating stomach ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5476815A JPS5476815A (en) | 1979-06-19 |
| JPS6213328B2 true JPS6213328B2 (en) | 1987-03-25 |
Family
ID=15276699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14078677A Granted JPS5476815A (en) | 1977-11-25 | 1977-11-25 | Composite agent for treating stomach ulcer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5476815A (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104083694A (en) * | 2014-06-30 | 2014-10-08 | 咸洪震 | Traditional Chinese medicine preparation for treating chronic gastritis and preparation method of traditional Chinese medicine preparation |
| CN104435811A (en) * | 2014-11-10 | 2015-03-25 | 青岛祥翔生物医药科技有限公司 | Traditional Chinese medicine for treating gastrointestinal diseases caused by stomach-yin deficiency |
| CN104474441B (en) * | 2014-11-27 | 2017-07-21 | 张雷 | A kind of medicine for treating stomach trouble |
| CN104474424A (en) * | 2014-12-01 | 2015-04-01 | 苏州卫生职业技术学院 | Medicine for treating gastritis and preparation method thereof |
| CN104383285B (en) * | 2014-12-01 | 2017-09-15 | 马喜超 | Treat Chinese medicine of stomach trouble and preparation method thereof |
| CN104800510A (en) * | 2015-05-07 | 2015-07-29 | 王小华 | Traditional Chinese medicine composition for treating stomach cancer |
| CN104906318A (en) * | 2015-06-19 | 2015-09-16 | 刘伟 | Traditional Chinese medicine formula for treating stomach troubles |
-
1977
- 1977-11-25 JP JP14078677A patent/JPS5476815A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5476815A (en) | 1979-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1318804B1 (en) | Iron compositions | |
| US8664268B2 (en) | Gallium compositions for the treatment of liver cancer and methods of use | |
| JP2003523944A (en) | Antiviral therapy using P-glycoprotein modifiers | |
| JPS6213328B2 (en) | ||
| US3230142A (en) | Oral contraceptive compositions and methods | |
| JPS59199630A (en) | Remedy for hypoovarianism | |
| JP2003519182A (en) | Preparations for the treatment of gynecomastia | |
| GB2248392A (en) | Composition to combat alcoholism | |
| EP0190851A1 (en) | Improved antiinflammatory composition | |
| JPS6263520A (en) | Antirheumatic agent | |
| US4544551A (en) | Antipeptic ulcer composition | |
| WO1996019220A1 (en) | A combination product comprising nitazoxanide and an anti-ulcer agent | |
| CN111714499B (en) | Pharmaceutical composition for treating polycystic ovarian syndrome | |
| AU2004283011A1 (en) | Pharmaceutical composition comprising oxoplatin, the salts and derivatives thereof | |
| CN111419853B (en) | Cucurbitacin and ibrutinib composition for treating breast cancer | |
| KR970006083B1 (en) | A pharmaceutical composition for treating gastrointestinal disorders | |
| JP4233766B2 (en) | Use of dienogest at high dosages | |
| US3800041A (en) | Analgesic compositions and methods | |
| US3102844A (en) | Oral iron-glucosamine hematinic composition and therapy | |
| ULC | Pr PACLitaxel INJECTION, USP | |
| Darzentas et al. | Effect of antacid on bioavailability of a sustained-release theophylline preparation | |
| US3126319A (en) | Method for the potentiation of anti- | |
| JPS6357520A (en) | Antiulcer agent | |
| JP2579187B2 (en) | Combination of central analgesic and forskolin as active ingredients | |
| KR970006084B1 (en) | A pharmaceutical composition for treating gastrointestinal disorders |